InCephalo Therapeutics
InCephalo Therapeutics is focused on developing innovative biologic drugs for CNS therapies, particularly targeting challenges like the Blood-Brain Barrier. They utilize proprietary 'compartment locked' technology to create tailor-made biological drugs that stay in the desired compartment and degrade if leaked, reducing systemic exposure and adverse effects. Their pipeline includes cytokine and antibody-based therapeutics for brain cancers and multiple sclerosis, with a focus on local administration to improve safety and efficacy.
Industries
Nr. of Employees
small (1-50)
InCephalo Therapeutics
Products
Compartment-restricted IL-12–class therapeutic candidate (locally administered)
A locally administered cytokine biologic engineered to remain in the target compartment (CNS/solid tumor microenvironment) and to reduce systemic exposure and toxicity while eliciting an anti-tumor immune response.
Compartment-restricted anti-CD20–class therapeutic candidate (intraventricular administration)
A locally administered B-cell–depleting antibody candidate designed to deplete B cells within the CNS compartment while minimizing peripheral B-cell depletion and systemic immunosuppression.
Compartment-restricted IL-12–class therapeutic candidate (locally administered)
A locally administered cytokine biologic engineered to remain in the target compartment (CNS/solid tumor microenvironment) and to reduce systemic exposure and toxicity while eliciting an anti-tumor immune response.
Compartment-restricted anti-CD20–class therapeutic candidate (intraventricular administration)
A locally administered B-cell–depleting antibody candidate designed to deplete B cells within the CNS compartment while minimizing peripheral B-cell depletion and systemic immunosuppression.
Expertise Areas
- CNS-targeted biologics
- Local drug delivery for the brain
- Immuno-oncology cytokine therapeutics
- B-cell targeted therapies for CNS autoimmune disease
Key Technologies
- Compartment-restricted biologic engineering
- Local/intraventricular administration
- Cytokine therapeutic development (IL-12 class)
- B-cell depleting antibody development (anti-CD20 class)